NXTC:NASDAQNextCure, Inc. analysis
Data as of Jun 13, 2026 - not real-time
- Latest price
- $2.08
- Risk: high
- 8/10High risk
Summary
Technical analysis points to a sharply bearish stance: the 20‑day SMA trails well beneath the 50‑day and 200‑day averages, the RSI sits in the extreme low zone, and the MACD line is below both its signal line and histogram, signaling a persistent downtrend.
Despite these signals, the stock sits at a fraction of its historical 52‑week high, with a massive upside potential estimated at over 800% and an “Extreme Greed” sentiment index, while volume is trending upward and volatility is exceptionally high. Recent coverage by Lucid Capital Markets introduced a buy recommendation with an 84% upside forecast, and the company is advancing several promising oncology and therapeutic programs, notably the dose‑optimization trial for its CDH6‑targeted ADC, which could catalyze a market‑driven price surge.
Despite these signals, the stock sits at a fraction of its historical 52‑week high, with a massive upside potential estimated at over 800% and an “Extreme Greed” sentiment index, while volume is trending upward and volatility is exceptionally high. Recent coverage by Lucid Capital Markets introduced a buy recommendation with an 84% upside forecast, and the company is advancing several promising oncology and therapeutic programs, notably the dose‑optimization trial for its CDH6‑targeted ADC, which could catalyze a market‑driven price surge.
Market outlook
Short term
< 1 yearNeutral
Model confidence6/106 out of 10
Key factors
- bearish technical indicators
- low current price vs. target
- increasing volume suggests building interest
Medium term
1–3 yearsPositive
Model confidence8/108 out of 10
Key factors
- large upside potential
- new oncology pipeline progress
- positive external buy recommendation
Long term
> 3 yearsPositive
Model confidence9/109 out of 10
Key factors
- potential breakthrough ADCs
- deep market undervaluation
- sustained high‑greed sentiment despite risks
Key metrics
Financial health
P/E Ratio-0.2
ROE-132.41%
ROA-66.71%
Debt/Equity14.52
P/B Ratio0.3
Op. Cash Flow$-49982000
Free Cash Flow$-27142876
Industry P/E24.8
Technical analysis
TrendBearish
RSI19.6
Support$2.00
Resistance$10.71
MA 20$5.46
MA 50$8.55
MA 200$9.88
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Target Price$19.33
Upside/Downside831.73%
GradeUndervalued
TypeGrowth
Risk assessment
Beta1.33
Volatility207.98%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.